Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.17
-$0.38(-13.19%)
At close: 4:00 PM EDT
$3.17
-$0.38(-13.19%)
Day’s Range― - ―
52-Week Range$1.14 - $24.42
Previous CloseN/A
Volume56.72K
Average Volume (3M)607.63K
Market Cap
$2.62M
Enterprise Value$12.45M
Total Cash (Recent Filing)$741.32K
Total Debt (Recent Filing)$6.56M
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Nov 12, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-54.17
Shares Outstanding2,236,324
10 Day Avg. Volume271,981
30 Day Avg. Volume607,632
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap4.76
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$8.00Price Target Upside152.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$6.54M
Bulls Say, Bears Say
Bulls Say
Commercialization PathwayThe Akron distribution agreement gives HCW11-006 a defined route toward commercialization through an established advanced-therapy network. This broadens potential use beyond internal development and could create recurring support and supply-related economics as adoption develops.
Proprietary Immunotherapy PlatformA proprietary platform spanning immune signaling, tumor microenvironment targets, cancer, and inflammatory disease provides multiple opportunities to advance candidates from a common scientific base. Platform reuse can improve development leverage and support longer-term pipeline durability.
Improved Balance SheetLower debt and positive equity provide a stronger capital structure than the company’s prior periods, reducing near-term leverage pressure while clinical programs advance. Although the position remains volatile, improved solvency supports greater financial flexibility than a heavily indebted balance sheet.
Bears Say
Persistent Cash BurnThe company is not yet self-funding its operations, with substantial operating and free cash outflows continuing over the trailing period. Persistent cash burn increases the need for additional financing and can constrain the pace of clinical development if capital access weakens.
Deep Operating LossesNegative EBIT, EBITDA, and a deeply negative net margin show that current activities do not cover operating costs. Until development programs or products generate materially stronger economics, ongoing losses will continue consuming capital and limit the durability of reported revenue improvement.
Limited Recurring Revenue BaseWithout established product sales, HCW Biologics remains dependent on financings and potential collaboration income while its candidates progress toward approval or broader commercialization. This funding model creates ongoing execution and dilution pressure before a recurring revenue base can develop.
HCW Biologics News
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $1.14 and its highest was $24.42 in the past 12 months.
What is HCW Biologics’s market cap?
HCW Biologics’s market cap is $2.62M.
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on Aug 14, 2026. The company reported -$11.58 earnings per share for the quarter, missing the consensus estimate of -$1.98 by -$9.6.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Undervalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is -1.35.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 2,236,324 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of -$11.58 in its last earnings report, missing expectations of -$1.98. Following the earnings report the stock price went down -8.376%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HCW Biologics
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$8.00
▲(152.37% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
10.44% Insiders
1.11% Mutual Funds
0.15% Other Institutional Investors
88.21% Public Companies and
Individual Investors